ArticleScientific reports2026
Foslevodopa-Foscarbidopa subcutaneous infusion in Parkinson's disease: a cross-cultural/cross-racial international multicentre comparative tolerability study (CRIM-FOS study).
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Continuous subcutaneous foslevodopa/foscarbidopa in advanced Parkinson's disease: A clinical workflow from 50 consecutive patients at a single U.S. center.Clinical parkinsonism & related disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advanced Parkinson's disease (APD) often presents challenges such as irregular gastric absorption and delayed gastric emptying, leading to significant and unpredictable fluctuations in both motor and non-motor symptoms. Our study is a real-world, open-label study of the tolerability and efficacy of subcutaneous infusion of Foslevodopa/Foscarbidopa (FL/FC) focus on comparing White Caucasian patients and non-White patient cohorts. A database of 50 patients with APD across four international centers, for the FL/FC therapy program was examined and analysed for racial/ethnicity breakdown, motor, nonmotor and quality of life measures and tolerability using established criteria. Participants underwent assessments at 6 and 12 months, making this one of the largest global cross-racial Caucasian (62%) and non-Caucasian patients (38%) Statistical analyses were performed using IBM SPSS Statistics version 31, with significance set at p < .05. In 50 patients (48% men, 38% of non-caucasian origin) with APD, Motor (UPDRS III) scores significantly declined from a baseline mean of 40.26 (SD = 10.21) to 24.84 (SD = 6.67) at 12 months (p < .001). Health-related quality of life, measured by the PDQ-8, improved significantly, with a mean difference of 6.11 (p < .001). The dropout rate was low at 10%, with an average time to dropout of 3 months (range: 2-4 months), primarily due to dose-limiting adverse effects like severe dyskinesias and financial constraints. Subcutaneous infusion of FL/FC significantly improves motor function and sleep quality in advanced Parkinson's patients, reduces caregiver burden, enhances quality of life and effective across racial backgrounds. Our study underscores the importance of careful patient selection and monitoring during dose adjustments to optimize long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.